Advertisement

The Scientist

» industry

Most Recent

image: Another CAR-T IPO

Another CAR-T IPO

By | April 6, 2015

Cellectis goes public for a whopping $228 million—nearly double the value the company filed for in February.

0 Comments

image: 23andMe Enters Drug Development

23andMe Enters Drug Development

By | March 12, 2015

The personal genomics firm announces plans to make medicines.

1 Comment

image: AbbVie Wins Bidding War for Cancer Drugmaker

AbbVie Wins Bidding War for Cancer Drugmaker

By | March 5, 2015

The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.

0 Comments

image: Pfizer to Acquire Hospira

Pfizer to Acquire Hospira

By | February 5, 2015

The pharmaceutical giant is purchasing the injectable drugmaker for about $15 billion.

0 Comments

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: 23andMe Partners with Pfizer

23andMe Partners with Pfizer

By | January 13, 2015

The personal genomics company strikes yet another deal to glean biomedically relevant information from its user data.

1 Comment

image: Shire Makes $5.2 Billion Buy

Shire Makes $5.2 Billion Buy

By | January 13, 2015

The Irish drugmaker moves on from its terminated sale to AbbVie to purchase New Jersey-based NPS Pharmaceuticals.

0 Comments

image: SAIC Founder Dies

SAIC Founder Dies

By | December 30, 2014

J. Robert Beyster, who established one of the largest research and engineering firms, passed away at age 90.

0 Comments

image: Roche Buys Bioinformatics Firm

Roche Buys Bioinformatics Firm

By | December 22, 2014

The pharmaceutical giant will pay an undisclosed price to acquire Bina Technologies.

0 Comments

image: Merck Buys Cubist for $8.4B

Merck Buys Cubist for $8.4B

By | December 11, 2014

Hours after the pharmaceutical giant announced the acquisition, a federal judge invalidated key patents behind the antibiotic maker’s most lucrative product.

0 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Biology Research
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Eppendorf
Eppendorf